This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The brain is the single most complex internal system in the body. That’s a no-brainer. But can you name the runner-up? (Bonus points for guessing what this has to do with healthcare AI.)
Two medical charities that last year gave $640 million to 200,000 struggling Americans are combining forces so they can expand their collective wherewithal.
Researchers: “Clinicians’ perceptions about older patients’ interest in and ability to use mobile health apps may negatively impact recommendation of mHealth apps and subsequent adoption by older adults.”
The patient, 78, presented with severe AR and no signs of calcification. She was considered a poor choice for surgery or traditional TAVR due to multiple risks. That is where the new-look ATLAS technique came in.
As of 2024, some 32% of hospital nurses indicated they remained unhappy on the job. No less troublingly, more than a quarter said they wanted to quit work outright.
A lot of people from a lot of organizations in a lot of countries are working to coordinate oversight of AI’s risks. A budding project seeks to bring many of these minds together to advance the worthy goal of building global consensus with scientific rigor.
The new AUC document was designed to help care teams know when and how to perform imaging-based cardiovascular evaluations on patients undergoing nonemergent, noncardiac surgery.
AI and patient care are “top of mind” for healthcare executives in 2024. The pairing seems opportune, since the surveyed leaders see the burgeoning technology as a key tool for improving the perennial mission.
The FDA ruled that this is a Class I recall due to the significant risks for patients. Customers are not required to return the devices, however. Inari Medical has provided updated warnings and recommendations that should be followed.
Researchers combined data from three well-known clinical trials—NOTION, Evolut Low Risk and PARTNER 3—and evaluated thousands of low-risk patients who presented with severe aortic stenosis.